Clinical Evidence Behind Prostate SBRT and The Raypilot® System
Explore the peer-reviewed studies and clinical posters that support prostate SBRT with The Raypilot® System. Each publication includes an editorial summary covering what the study shows, why it matters, and what it means for clinical practice.
-
Electromagnetic transmitter-based prostate gating for dose-escalated SBRT
Evaluates intrafraction motion magnitude and gating frequency using The Raypilot System's EM tracking. Reports the proportion of fractions where gating was triggered and the clinical impact.
Why it matters: The study shows that the Raypilot System can be easily incorporated into routine prostate LINAC-based SBRT workflows. Its use enabled the safe application of a 2 mm CTV-to-PTV margin. The study also shows that without intrafraction motion control, prostate motion would have gone undetected.
-
ABRUPT: Toxicity and quality of life with dose-escalated SBRT using The Raypilot System
Prospective study of ablative radiotherapy for unfavourable prostate tumours with The Raypilot System, using one single fraction. Reports toxicity rates and quality-of-life outcomes at dose escalation.
Why it matters: Raypilot System-specific clinical data. Measured outcomes from patients treated with this system in routine clinical practice.
-
PACE-C: Moderate hypofractionation vs. SBRT, early toxicity
Head-to-head comparison of moderate hypofractionation and SBRT. Early toxicity results confirm that the increased toxicity seen with SBRT is predominantly urethra-related; the exact issue that The Raypilot System's urethra visualisation addresses. moderate hypofractionation and SBRT
Why it matters: The residual toxicity risk in SBRT is manageable with the right tools. Urethra-sparing technique is the key, and that requires knowing where the urethra is during delivery
-
PACE-B: Phase 3 trial of SBRT in localised prostate cancer
874 patients randomised to SBRT (5 fractions) or moderate hypofactionation or conventional fractionation (20 or 39 fractions). SBRT demonstrated non-inferiority for biochemical or clinical failure, reducing treatment from 4 weeks to 1–2 weeks with no increase in late toxicity.
Why it matters: This is the largest randomised trial confirming SBRT as a standard of care. With The Raypilot System's continuous motion tracking, margins can be tightened further, supporting the move from selected cases to routine practice.